Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
5.70
-0.34 (-5.63%)
Nov 21, 2024, 12:02 PM EST - Market open
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $26.08M in the quarter ending September 30, 2024, with 147.62% growth. This brings the company's revenue in the last twelve months to $65.18M, up 37.64% year-over-year. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.
Revenue (ttm)
$65.18M
Revenue Growth
+37.64%
P/S Ratio
22.76
Revenue / Employee
$130,368
Employees
500
Market Cap
1.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
Dec 31, 2019 | 2.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Patterson Companies | 6.53B |
Integra LifeSciences Holdings | 1.56B |
Azenta | 656.32M |
NovoCure | 577.74M |
AtriCure | 447.57M |
Galapagos NV | 290.09M |
Tarsus Pharmaceuticals | 129.62M |
RxSight | 128.29M |
RXRX News
- 1 day ago - Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery - GlobeNewsWire
- 8 days ago - Recursion and Exscientia Shareholders Approve the Proposed Combination - GlobeNewsWire
- 8 days ago - Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden - GlobeNewsWire
- 22 days ago - Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - GlobeNewsWire
- 4 weeks ago - Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection - GlobeNewsWire
- 6 weeks ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 7 weeks ago - Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment - CNBC
- 7 weeks ago - Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma - GlobeNewsWire